EP1161255A4 - METHODS AND COMPOSITIONS FOR THE TREATMENT OF DYSERECTION - Google Patents

METHODS AND COMPOSITIONS FOR THE TREATMENT OF DYSERECTION

Info

Publication number: EP1161255A4
Authority: EP; European Patent Office
Prior art keywords: dyserection; compositions; treatment; methods
Prior art date: 1999-03-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP00916081A

Other languages

German (de)

French (fr)

Other versions

EP1161255A2 (en

Inventor

Elizabeth Stoner

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Merck and Co Inc

Original Assignee

Merck and Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-08

Filing date

2000-03-03

Publication date

2002-07-17

2000-03-03 Application filed by Merck and Co Inc filed Critical Merck and Co Inc

2001-12-12 Publication of EP1161255A2 publication Critical patent/EP1161255A2/en

2002-07-17 Publication of EP1161255A4 publication Critical patent/EP1161255A4/en

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Reproductive Health (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gynecology & Obstetrics (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP00916081A 1999-03-08 2000-03-03 METHODS AND COMPOSITIONS FOR THE TREATMENT OF DYSERECTION Withdrawn EP1161255A4 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US12324499P	1999-03-08	1999-03-08
US123244P		1999-03-08
PCT/US2000/005711 WO2000053148A2 (en)	1999-03-08	2000-03-03	Methods and compositions for treating erectile dysfunction

Publications (2)

Publication Number	Publication Date
EP1161255A2 EP1161255A2 (en)	2001-12-12
EP1161255A4 true EP1161255A4 (en)	2002-07-17

Family

ID=22407530

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP00916081A Withdrawn EP1161255A4 (en)	1999-03-08	2000-03-03	METHODS AND COMPOSITIONS FOR THE TREATMENT OF DYSERECTION

Country Status (4)

Country	Link
EP (1)	EP1161255A4 (en)
AU (1)	AU3724400A (en)
CA (1)	CA2362918A1 (en)
WO (1)	WO2000053148A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6403597B1 (en)	1997-10-28	2002-06-11	Vivus, Inc.	Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6548490B1 (en) *	1997-10-28	2003-04-15	Vivus, Inc.	Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
IL135817A0 (en) *	1999-04-30	2001-05-20	Lilly Icos Llc	Phosphodiesterase enzyme inhibitors and their use in pharmaceutical articles
US6943166B1 (en)	1999-04-30	2005-09-13	Lilly Icos Llc.	Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
US7235625B2 (en)	1999-06-29	2007-06-26	Palatin Technologies, Inc.	Multiple agent therapy for sexual dysfunction
US7176279B2 (en)	2000-06-28	2007-02-13	Palatin Technologies, Inc.	Cyclic peptide compositions and methods for treatment of sexual dysfunction
BR0012863A (en)	1999-08-03	2002-04-16	Lilly Icos Llc	Beta-Carboline Pharmaceutical Compositions
TWI265925B (en)	1999-10-11	2006-11-11	Pfizer	Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
AU2002238106A1 (en)	2001-02-13	2002-08-28	Palatin Technologies, Inc.	Melanocortin metallopeptides for treatment of sexual dysfunction
CA2453609C (en) *	2001-07-18	2010-05-04	Merck & Co., Inc.	Bridged piperidine derivatives as melanocortin receptor agonists
WO2004005324A2 (en)	2002-07-09	2004-01-15	Palatin Technologies, Inc.	Peptide composition for treatment of sexual dysfunction
US11590209B2 (en)	2020-01-21	2023-02-28	Palatin Technologies, Inc.	Use of bremelanotide in patients with controlled hypertension

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5962528A (en) *	1991-07-03	1999-10-05	Scott; Nathan Earl	Prostaglandin E2 /F2α combination for treating impotence
EP0611248B1 (en) *	1993-02-10	2000-03-22	B.M.R.A. Corporation B.V.	Pharmaceutical composition for treating impotence containing an alpha-1-inhibitor and an alpha-2 inhibitor
EP0696919B1 (en) *	1993-04-05	2002-01-30	Competitive Technologies, Inc.	Diagnosis and treatment of erectile dysfunction
GB9301192D0 (en) *	1993-06-09	1993-06-09	Trott Francis W	Flower shaped mechanised table
GB9423911D0 (en) *	1994-11-26	1995-01-11	Pfizer Ltd	Therapeutic agents
US5731339A (en) *	1995-04-28	1998-03-24	Zonagen, Inc.	Methods and formulations for modulating the human sexual response
GB9514464D0 (en) *	1995-07-14	1995-09-13	Glaxo Lab Sa	Medicaments
US5932538A (en) *	1996-02-02	1999-08-03	Nitromed, Inc.	Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US5994294A (en) *	1996-02-02	1999-11-30	Nitromed, Inc.	Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US6037346A (en) *	1997-10-28	2000-03-14	Vivus, Inc.	Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
HRP20000407A2 (en) *	1997-12-16	2000-10-31	Pfizer Prod Inc	Combination effective for the treatment of impotence
CA2314369A1 (en) *	1997-12-18	1999-06-24	Nathan Earl Scott	Prostaglandin e2/f2.alpha. combination for treating impotence and enhancing sexual arousal
GT199900061A (en) *	1998-05-15	2000-10-14	Pfizer	PHARMACEUTICAL FORMULATIONS.
WO1999059584A1 (en) *	1998-05-20	1999-11-25	Schering Corporation	Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
US6124461A (en) *	1998-05-26	2000-09-26	Saint Louis University, Health Services Center, Research Administration	Compounds, compositions, and methods for treating erectile dysfunction
US6200591B1 (en) *	1998-06-25	2001-03-13	Anwar A. Hussain	Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
US6007824A (en) *	1998-07-09	1999-12-28	Duckett; Melvin J.	Natural composition and method for the treatment of sexual dysfunction

2000
- 2000-03-03 EP EP00916081A patent/EP1161255A4/en not_active Withdrawn
- 2000-03-03 CA CA002362918A patent/CA2362918A1/en not_active Abandoned
- 2000-03-03 AU AU37244/00A patent/AU3724400A/en not_active Abandoned
- 2000-03-03 WO PCT/US2000/005711 patent/WO2000053148A2/en not_active Ceased

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HEDLUND-H ET AL.: "Pharmacotherapy in erectile dysfunction agents for self-injection programs and alternative application methods", SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, vol. 179, no. Suppl, 1996, pages 129 - 138, XP001064596 *
HUNTER WESSELS ET AL.: "Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study", THE JOURNAL OF UROLOGY, vol. 160, 1998, pages 389 - 393, XP001064550 *
See also references of WO0053148A3 *

Also Published As

Publication number	Publication date
AU3724400A (en)	2000-09-28
EP1161255A2 (en)	2001-12-12
WO2000053148A2 (en)	2000-09-14
CA2362918A1 (en)	2000-09-14
WO2000053148A3 (en)	2000-12-14

Publication	Publication Date	Title
EP0866710A4 (en)	2001-07-11	COMPOSITIONS AND METHODS FOR THE TREATMENT OF BONE DEFICITS
FR12C0077I2 (en)	2013-08-16	Composition for the treatment of genital warts
EP1438062A4 (en)	2005-06-01	METHODS AND COMPOSITIONS FOR THE TREATMENT OF SKIN LESIONS
FR07C0046I2 (en)	2008-05-09	BETA-L-2'-DESOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B
MA27374A1 (en)	2005-06-01	ESTER OF 2'-C-METHYL-3'-O-L-VALINE AND RIBOFURANOSYL CYTIDINE FOR THE TREATMENT OF FLAVIVIRIDAE INFECTIONS
DE60019556D1 (en)	2005-05-25	2-AMINO-BENZOXAZINE DERIVATIVES FOR THE TREATMENT OF FATIBILITY
DE10082139T1 (en)	2001-10-04	Composition for the treatment of friction pairs
DE60019555D1 (en)	2005-05-25	2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF FATIBILITY
EP1446114A4 (en)	2005-05-25	COMPOSITIONS AND METHODS FOR TREATING OSTEOPOROSIS
EP1383527A4 (en)	2004-07-14	METHODS AND COMPOSITIONS FOR TREATING ORAL AND ESOPHAGIAN LESIONS
ID27191A (en)	2001-03-08	METHODS FOR TREATMENT OF INSOMNIA
NO20014314D0 (en)	2001-09-05	Compositions and methods for the treatment of staphylococcal infection
DE60136477D1 (en)	2008-12-18	RETINOIDES FOR THE TREATMENT OF EMPHYSEM
EP0975654A4 (en)	2002-04-10	COMPOSITIONS AND METHODS FOR THE TREATMENT OF CYTOMEGALOVIRUS INFECTIONS
DE69519577D1 (en)	2001-01-11	PREDNISOLONMETASULFOBENZOATE COMPOSITION FOR TREATING INFLAMMATORY DISEASE OF THE COLON
EP1161255A4 (en)	2002-07-17	METHODS AND COMPOSITIONS FOR THE TREATMENT OF DYSERECTION
EP1359885A4 (en)	2005-03-16	INHIBITORS OF NOS FOR THE TREATMENT OF WRINKLES
IL155174A0 (en)	2003-10-31	Methods and compositions for the treatment of inflammatory diseases
ID27214A (en)	2001-03-08	TRIAZOLOPIRIDINA FOR TREATMENT OF TROMBOSIS DISORDERS
FR2800614B1 (en)	2002-01-04	COMPOSITION FOR THE TREATMENT OF RESPIRATORY INFECTIONS
FR2758465B1 (en)	1999-04-09	COMPOSITION FOR THE TREATMENT OF ASBESTOS
DE69913380D1 (en)	2004-01-15	COMPOSITION FOR THE TREATMENT OF PERIODONTAL DISEASES
DE60001255D1 (en)	2003-02-27	Composition for the treatment of polyester fiber
NO20001758D0 (en)	2000-04-05	Methods and compositions for the treatment of arthritis
EP1575503A4 (en)	2008-04-02	COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING INFECTIONS

Legal Events

Date	Code	Title	Description
2001-10-26	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2001-12-12	17P	Request for examination filed	Effective date: 20011008
2001-12-12	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2001-12-12	AX	Request for extension of the european patent	Free format text: AL PAYMENT 20011008;LT PAYMENT 20011008;LV PAYMENT 20011008;MK PAYMENT 20011008;RO PAYMENT 20011008;SI PAYMENT 20011008
2002-07-17	A4	Supplementary search report drawn up and despatched	Effective date: 20020531
2002-07-17	AK	Designated contracting states	Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2002-07-17	RIC1	Information provided on ipc code assigned before grant	Free format text: 7A 61K 38/08 A, 7A 61K 31/415 B, 7A 61K 31/505 B, 7A 61K 38/12 B, 7A 61P 15/10 B, 7A 61K 38/12 J, 7A 61K 31:00 J
2003-01-31	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2003-03-19	18D	Application deemed to be withdrawn	Effective date: 20020823